We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 5,151

The battle over sitagliptin between Merck and Glenmark reaches the Supreme Court
  • Lakshmikumaran & Sridharan
  • India
  • May 27 2015

Nearly two years after Merck initiated an infringement action against Glenmark before the Delhi High Court over its Patented diabetics drug


Filling in some Actavis gaps - California Supreme Court adopts structured rule of reason test for antitrust scrutiny of pay-for-delay settlements
  • Locke Lord LLP
  • USA
  • May 27 2015

A sweeping new opinion from the California Supreme Court revives California Cartwright Act challenges to pay-for-delay pharmaceutical patent


Supreme Court’s decision in Commil v. Cisco: big win for pharmaceutical industry
  • Patterson Belknap Webb & Tyler LLP
  • USA
  • May 27 2015

On May 26, 2015, the Supreme Court reversed the Federal Circuit's decision in Commil USA, LLC v. Cisco Systems, Inc. and held that a defendant's


Canadian Appeal Court itching to consider patented medical treatments
  • Bereskin & Parr LLP
  • Canada
  • May 25 2015

The Canadian Federal Court of Appeal has recently indicated its interest in revisiting patentability of methods of medical treatment in future in a


Kyle Bass files fifteenth IPR petition
  • Fish & Richardson PC
  • USA
  • May 23 2015

Since our last posting on April 23, Kyle Bass has filed three additional IPR petitions, bringing his grand total to fifteen (none of which have yet


Fed. Cir. Confirms 271(e)(1) safe harbor applies to post-approval development of clinical data for citizen petition and supplemental new drug application
  • Brinks Gilson & Lione
  • USA
  • May 22 2015

On appeal from the District of Maryland, the Federal Circuit held in Classen Immunotherapies, Inc. v. Elan Pharmaceuticals, Inc., that the §


Patent safe harbor applies to supplemental new drug applications
  • Foley & Lardner LLP
  • USA
  • May 21 2015

On May 13, 2015, the Federal Circuit confirmed in Classen Immunotherapies, Inc. v. Elan Pharmaceuticals, Inc. that the safe harbor provisions of 35 U


“Pay for delay” gets a closer look in Canada
  • Sotos LLP
  • Canada
  • May 21 2015

The Canadian Competition Bureau is taking a “keen interest” in patent litigation settlements between brand and generic drug manufacturers


Malaria Viagra unhappy ending for parasites
  • Watermark Patent & Trade Marks Attorneys
  • Australia
  • May 20 2015

A recent study has shown that the active ingredient in Viagra (sildenafil) has the capacity to slow the spread of malaria parasites. The study


Life Sciences IPR Final Written Decision; Touches on Written Description, 102 and 103
  • Fish & Richardson PC
  • USA
  • May 20 2015

Life Sciences IPR Final Written Decision; Touches on Written Description (in determining whether or not priority claim is valid), 102 and 103